Fructose-mediated damage to lens alpha-crystallin: prevention by pyruvate.
Post-translational modifications in lens crystallins due to glycation and oxidation have been suggested to play a significant role in the development of cataracts associated with aging and diabetes. We have previously shown that alpha-keto acids, like pyruvate, can protect the lens against oxidation. We hypothesize that they can also prevent the glycation of proteins competitively by forming a Schiff base between their free keto groups and the free -NH(2) groups of protein as well as subsequently inhibit the oxidative conversion of the initial glycation product to advanced glycation end products (AGE). The purpose of this study was to investigate these possibilities using purified crystallins. The crystallins isolated from bovine lenses were incubated with fructose in the absence and presence of pyruvate. The post-incubation mixtures were analyzed for fructose binding to the crystallins, AGE formation, and the generation of high molecular weight (HMW) proteins. In parallel experiments, the keto acid was replaced by catalase, superoxide dismutase (SOD), or diethylene triaminepentaacetic acid (DTPA). This was done to ascertain oxidative mode of pyruvate effects. Interestingly, the glycation and consequent formation of AGE from alpha-crystallin was more pronounced than from beta-, and gamma-crystallins. The changes in the crystallins brought about by incubation with fructose were prevented by pyruvate. Catalase, SOD, and DTPA were also effective. The results suggest that pyruvate prevents against fructose-mediated changes by inhibiting the initial glycation reaction as well as the conversion of the initial glycated product to AGE. Hence it is effective in early as well as late phases of the reactions associated with the formation of HMW crystallin aggregates.
Zhao
W
W
Department of Ophthalmology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Devamanoharan
P S
PS
Varma
S D
SD
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D002374:Catalase / Q000494:pharmacology; D002386:Cataract / Q000209:etiology / Q000378:metabolism; D002417:Cattle; D003459:Crystallins / Q000737:chemistry / Q000187:drug effects*; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000378:metabolism; D005632:Fructose / Q000633:toxicity*; D006031:Glycosylation / Q000187:drug effects; D010084:Oxidation-Reduction; D004369:Pentetic Acid / Q000494:pharmacology; D019289:Pyruvic Acid / Q000494:pharmacology*; D012545:Schiff Bases / Q000737:chemistry; D013482:Superoxide Dismutase / Q000494:pharmacology
D000975:Antioxidants; D003459:Crystallins; D012545:Schiff Bases; D005632:Fructose; D004369:Pentetic Acid; D019289:Pyruvic Acid; D002374:Catalase; D013482:Superoxide Dismutase